title: Quetiapine treatment and improved cognitive functioning in borderline personality disorder.
abstract: OBJECTIVE
  We aimed to assess whether executive functioning improved over time in a sample of borderline personality disorder (BPD) subjects that took part in a quetiapine treatment trial.
  
  
  METHODS
  Performance on the following neurocognitive tasks was assessed at enrolment and at the end of the 12 weeks quetiapine treatment: Trail Making Task, Word Fluency Task and Tower of London Task. Forty-one BPD patients were recruited, of whom 32 completed the trial. An intention-to-treat analysis with a mixed linear model was applied.
  
  
  RESULTS
  The data show that participants significantly improved on most executive functioning measures. Patients' scores decreased significantly (mean [SD] difference; p-value) on the Trail Making Task Part A (11.7 [2.3]; p < 0.0001), Part B (51.8 [9.2]; p < 0.0001) and 'B minus A' (40.1 [8.2]; p < 0.0001), on a Phonological (15.9 [1.6]; p < 0.0001) and Semantic (9.8 [1.1]; p < 0.0001) Verbal Fluency tasks, and on the Tower of London total correct score (2.5 [0.4]; p < 0.0001), total move score (29.5 [4.5]; p < 0.0001) and total time (172.9 [35.8]; p < 0.0001).
  
  
  CONCLUSIONS
  In this study we have demonstrated that executive functioning in BPD is improved after treatment with quetiapine. Neurocognitive measures of executive functioning should be considered as valuable outcomes in the study of treatment efficacy in BPD.
authors: Department of Psychiatry and Medical Psychology, University Hospital Ghent, Gent, Belgium. frederique.vandeneynde@iop.kcl.ac.uk
authors: Frederique
authors: F
authors: Van den Eynde
authors: Sofie
authors: S
authors: De Saedeleer
authors: Kris
authors: K
authors: Naudts
authors: Jemma
authors: J
authors: Day
authors: Caroline
authors: C
authors: Vogels
authors: Cornelis
authors: C
authors: van Heeringen
authors: Kurt
authors: K
authors: Audenaert
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001883:Borderline Personality Disorder / Q000188:drug therapy* / Q000503:physiopathology; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D003987:Dibenzothiazepines / Q000627:therapeutic use*; D056344:Executive Function / Q000187:drug effects; D005260:Female; D006801:Humans; D016014:Linear Models; D008297:Male; D009483:Neuropsychological Tests; D000069348:Quetiapine Fumarate; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate